Kidney Cancer Coverage from Every Angle
Advertisement
Advertisement

Intermittent Nivolumab Dosing for Metastatic Renal Cell Carcinoma

By: Hillary Ojeda
Posted: Wednesday, July 24, 2019

According to a prospective study published in the Journal for ImmunoTherapy of Cancer, intermittent nivolumab dosing merits further evaluation as a feasible treatment in patients with metastatic renal cell carcinoma. Moshe C. Ornstein, MD, of the Cleveland Clinic, and colleagues suggest that despite its limitations, the phase II clinical trial may lead to better treatment for patients who have received prior antiangiogenic therapy.

“Ongoing trials of intermittent treatment will prospectively identify patients who can benefit from [an] extended break without compromising clinical outcomes,” the investigators concluded.

Fourteen patients were enrolled and received 12 weeks of nivolumab treatment. Those who had progressive disease based on Response Evaluation Criteria in Solid Tumors (RECIST PD) were not included in the trial. Intermittent nivolumab dosing continued, depending on the patients’ tumor burden, until RECIST PD. Of the total, 12 patients were at intermediate risk by International Metastatic Renal Cell Carcinoma Database Consortium criteria, and all patients had had nephrectomy. The objective response rate was 29%, and the median progression-free survival was 7.97 months.

Five patients fulfilled the criteria for the intermittent phase of the trial and agreed to receive intermittent treatment. One patient restarted therapy after the median follow-up of 48 weeks. The other four patients had a sustained response for a median of 34 weeks without treatment and a median sustained tumor burden decrease of 46.5%. None of the patients had RECIST PD while off therapy.

Disclosure: The study authors’ disclosure information may be found at jitc.biomedcentral.com.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.